BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29799325)

  • 21. End-of-life care for lung cancer patients in the United States and Ontario.
    Warren JL; Barbera L; Bremner KE; Yabroff KR; Hoch JS; Barrett MJ; Luo J; Krahn MD
    J Natl Cancer Inst; 2011 Jun; 103(11):853-62. PubMed ID: 21593012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age and gender differences in medicare expenditures and service utilization at the end of life for lung cancer decedents.
    Shugarman LR; Bird CE; Schuster CR; Lynn J
    Womens Health Issues; 2008; 18(3):199-209. PubMed ID: 18457755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Targeted Therapy on the Quality of End-of-Life Care for Patients With Non-Small-Cell Lung Cancer: A Population-Based Study in Taiwan.
    Tsai HY; Chung KP; Kuo RN
    J Pain Symptom Manage; 2018 Mar; 55(3):798-807.e4. PubMed ID: 29056563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of End-of-Life Oncologic Care for Stage IV Non-small Cell Lung Cancer in the United States.
    Haque W; Verma V; Butler EB; Teh BS
    Anticancer Res; 2019 Jun; 39(6):3137-3140. PubMed ID: 31177159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
    Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
    J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States?
    Hopson S; Casebeer A; Stemkowski S; Antol DD; Tao Z; Howe A; Patton J; Small A; Masaquel A
    J Med Econ; 2018 Feb; 21(2):152-162. PubMed ID: 28945163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy.
    Soliman AM; Bonafede M; Farr AM; Castelli-Haley J; Winkel C
    J Manag Care Spec Pharm; 2016 May; 22(5):573-87. PubMed ID: 27123918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Family Perspectives on Aggressive Cancer Care Near the End of Life.
    Wright AA; Keating NL; Ayanian JZ; Chrischilles EA; Kahn KL; Ritchie CS; Weeks JC; Earle CC; Landrum MB
    JAMA; 2016 Jan; 315(3):284-92. PubMed ID: 26784776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.
    Yi E; Dai D; Piao OW; Zheng JZ; Park Y
    J Manag Care Spec Pharm; 2021 Jan; 27(1):27-36. PubMed ID: 33043820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies.
    Korytowsky B; Radtchenko J; Nwokeji ED; Tuell KW; Kish JK; Feinberg BA
    Am J Manag Care; 2018 Oct; 24(20 Suppl):S439-S447. PubMed ID: 30362811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.
    Zeng X; Karnon J; Wang S; Wu B; Wan X; Peng L
    PLoS One; 2012; 7(10):e48323. PubMed ID: 23118985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
    Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
    J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of a Step Therapy for Guanfacine Extended-Release on Medication Utilization and Health Care Expenditures Among Individuals Receiving Treatment for ADHD.
    Suehs BT; Sikirica V; Mudumby P; Dufour R; Patel NC
    J Manag Care Spec Pharm; 2015 Sep; 21(9):793-802, 802a-802i. PubMed ID: 26308226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.
    Luskin AT; Antonova EN; Broder MS; Chang E; Raimundo K; Solari PG
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1117-1124. PubMed ID: 29083971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
    Chen CC; Parikh K; Abouzaid S; Purnomo L; McGuiness CB; Hussein M; Wade RL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):236-246. PubMed ID: 28125372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
    Moll K; Sun SX; Ellis JJ; Howe A; Amin A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.
    Chastek B; Kulakodlu M; Valluri S; Seal B
    Postgrad Med; 2013 Mar; 125(2):73-82. PubMed ID: 23816773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.